skip to Main Content
Neurology trials in California
#Study NameSponsorLocations
1A Study to Confirm Safety and Efficacy of BAN2401 in Participants With Early Alzheimer's Disease (Clarity AD)Eisai Inc.
  • Neurology Center of North Orange County, Fullerton
  • Irvine Clinical Research Recruiting, Irvine
  • Pacific Neuroscience Medical Group, Oxnard
  • View More
2GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer's DiseaseCortexyme Inc.
  • ATP Clinical Research, Inc., Costa Mesa
  • Standford University, Palo Alto
  • CITRIALS, Santa Ana
  • View More
3A Study of Semorinemab in Patients With Moderate Alzheimer's Disease
Genentech, Inc.
  • Pharmacology Research Institute, Los Alamitos
  • Stanford University; Stanford Clinical Cancer Ctr, Palo Alto
  • View More
4SI-6603 (Condoliase) Study for Lumbar Disc Herniation (Discovery 6603 Study)Seikagaku Corporation
  • Coastal Pain and Spinal Diagnostics, Carlsbad, California, United States, 92009
  • Pain Medicine Associates, Inc., Fountain Valley, California, United States, 92708
  • View More
5An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS) (VALOR (Part C))Biogen
  • University of California San Diego Medical Center, La Jolla, California, United States, 92093-0949
  • California Pacific Medical Center, San Francisco, California, United States, 94115
  • View More
6Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose QuetiapineACADIA Pharmaceuticals Inc.
  • Sutter Institute for Medical Research, Sacramento, California, United States, 95816
  • View More
7Study of CVN424 in Parkinson's Disease Patients With Motor FluctuationsCerevance Beta, Inc.
  • Collaborative Neuroscience Network, Long Beach, California, United States, 90806
  • SC3 Research - Pasadena, Pasadena, California, United States, 91105
  • View More
8A Clinical Study of NLY01 in Patient's With Early Parkinson's DiseaseNeuraly, Inc.
  • University of California, Irvine, California, United States, 92697
  • SC3 Research, Pasadena, California, United States, 91105
  • View More
9A Randomized Double-Blinded Placebo-Controlled Exploratory Study of Intravenous Immunoglobulin (NewGam 10%) in Amnestic Mild Cognitive ImpairmentSutter Health
  • Sutter Neuroscience Medical Group, Sacramento, California, United States, 95816
10Effects of Brain Beta Amyloid on Postoperative Cognition and 18F-AV-45-A14: Clinical Evaluation of Florbetapir F 18 (18F-AV-45)University of California, San Francisco
  • San Francisco VA Medical Center, San Francisco, California, United States, 94121
11A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's DiseaseEisai Inc.
12Curcumin and Yoga Exercise Effects in Veterans at Risk for Alzheimer's DiseaseVA Office of Research and Development
  • VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California, United States, 90073
13Phase 2a Levetiracetam Trial for AD-Associated Network HyperexcitabilityUniversity of Minnesota
  • UCSF, San Francisco, California, United States, 94158
14Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)Eli Lilly and Company
15A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Efficacy and Safety Study of Gantenerumab in Patients With Mild Alzheimer's Disease; Part II: Open-Label Extension For Participating PatientsHoffmann-La Roche
16A Phase 3, Multicenter, Long Term, Extension Study of the Safety and Efficacy of AVP-786 (Deuterated [d6] Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's TypeAvanir Pharmaceuticals
17A Phase III Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's DiseaseAZTherapies, Inc.
18Long-Term Nicotine Treatment of Mild Cognitive ImpairmentUniversity of Southern California
19Lifestyle Enriching Activities for Research in Neuroscience Intervention Trial: LEARNit StudyUniversity of Southern California
  • University of Southern California, Los Angeles, California, United States, 90032
20A Phase IIa Study of Allogeneic Human Mesenchymal Stem Cells in Subjects With Mild to Moderate Dementia Due to Alzheimer's DiseaseStemedica Cell Technologies, Inc.
  • John Wayne Cancer Institute @ Providence St. John's Health Center, Santa Monica, California, United States, 90404
21A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's DiseaseAbbVie
22A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamic (PD) Effects of Posiphen® in Subjects With Early Alzheimer's Disease (AD)Annovis Bio Inc.
  • UCSD Alzheimer's Disease Research Center, La Jolla, California, United States, 92037
23Longitudinal Cohort Study of Resource Use and Cost of Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease in the United States (GERAS-US)Eli Lilly and Company
  • California Pharmaceutical Research Institute, Anaheim, California, United States, 92804
  • Advanced Research Center, Anaheim, California, United States, 92805
24A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's DiseaseEisai Co., Ltd.
  • Facility #1, Colton, California, United States, 92324
25A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's DiseaseEisai Co., Ltd.
26A Double-Blind-Randomized, Placebo-Controlled Adaptive Design Trial of Nicotinamide in Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease DementiaUniversity of California, Irvine
  • University of California, Irvine, Irvine, California, United States, 92697
  • University of California, Los Angeles, Los Angeles, California, United States, 90095
27More Than a Movement Disorder: Applying Palliative Care to Parkinson's DiseaseUniversity of Colorado, Denver
  • University of California, San Francisco, San Francisco, California, United States, 94143
28Escitalopram for Agitation in Alzheimer's DiseaseJHSPH Center for Clinical Trials
29A Phase 1b, 12-Month, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Salsalate in Patients With Mild to Moderate Alzheimer's DiseaseAdam Boxer
  • University of California, San Diego, San Diego, California, United States, 92093
  • University of California, San Francisco, San Francisco, California, United States, 94158
30A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of MTAU9937A in Patients With Prodromal to Mild Alzheimer's DiseaseGenentech, Inc.
  • California Clinical Trials, Glendale, California, United States, 91206
31Study of Non-Invasive Deep Brain Stimulation With Low Intensity Focused Ultrasound Pulse (LIFUP) for Mild Cognitive Impairment (MCI) and Mild Alzheimer's Disease (AD)University of California, Los Angeles
  • UCLA Longevity Center, Los Angeles, California, United States, 90095
32Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's DiseaseBiogen
33Examining the Impact of Grape Consumption on Brain Metabolism and Neuropsychological Performance in Patients Undergoing Neuroimaging Evaluation for Cognitive Decline: A Double-blinded Placebo Controlled Expansion StudyUniversity of California, Los Angeles
  • University of California, Los Angeles, Los Angeles, California, United States, 90095
34Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's DiseaseEli Lilly and Company
35A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-design Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's TypeAvanir Pharmaceuticals
36Examining the Impact of Photobiomodulation on Cognition, Behavior, and Biomarkers of Alzheimer's DiseaseUniversity of California, San Francisco
  • VA Health Care System, San Francisco, California, United States, 94121
  • UCSF Memory and Aging Center, San Francisco, California, United States, 94158
37Coaching for Cognition in Alzheimer's (COCOA)Hoag Memorial Hospital Presbyterian
  • Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States, 92663
38A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of Gantenerumab in Patients With Early (Prodromal to Mild) Alzheimer's DiseaseHoffmann-La Roche
39A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of Gantenerumab in Patients With Early (Prodromal to Mild) Alzheimer's DiseaseHoffmann-La Roche
  • CITrials, Inc., Bellflower, California, United States, 90706
40Randomized, Double-Blind, Placebo-Controlled, Three-Arm, 12-Month, Safety and Efficacy Study of TRx0237 Monotherapy in Subjects With Alzheimer's Disease Followed by a 12-Month Open-Label TreatmentTauRx Therapeutics Ltd
41A Dyadic Sleep Intervention for Alzheimer's Disease Patients and Their CaregiversUniversity of California, Los Angeles
  • University of California Los Angeles, Los Angeles, California, United States, 90095
  • Veterans Affairs Greater Los Angeles Healthcare System, North Hills, California, United States, 91343
42A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of AGB101on Slowing Progression of Mild Cognitive Impairment Due to Alzheimer's DiseaseAgeneBio
  • Senior Clinical Trials, Inc., Laguna Hills, California, United States, 92653
43Reducing Risk for Alzheimer's Disease in High-Risk Women Through Yogic Meditation TrainingUniversity of California, Los Angeles
  • UCLA Semel Institute, Los Angeles, California, United States, 90095
44Assessment of Safety, Tolerability, and Efficacy of LY3303560 in Early Symptomatic Alzheimer's DiseaseEli Lilly and Company
45Mindfulness Meditation and Insomnia in Alzheimer Disease Caregivers: Inflammatory and Biological Aging MechanismsUniversity of California, Los Angeles
  • Cousins Center for Psychoneuroimmunology, UCLA Neuropsychiatric Institute, Los Angeles, California, United States, 90095
46A Phase 3, 12-Week, Multicenter, Randomized, Double-blind, Placebo-controlled, 2-Arm, Fixed-dose Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's TypeOtsuka Pharmaceutical Development & Commercialization, Inc.
  • For additional information regarding sites, contact 844-687-8522, Los Angeles, California, United States, 90036
47A Phase 2 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of BHV-4157 in Patients With Mild to Moderate Alzheimer's DiseaseBiohaven Pharmaceuticals, Inc.
48The Delivery of Essential Fatty Acids to the BrainUniversity of Southern California
  • USC Keck School of Medicine, Los Angeles, California, United States, 90033
49ADvance II: A 12-month Double-blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of Deep Brain Stimulation of the Fornix (DBS-f) in Patients With Mild Probable Alzheimer's DiseaseFunctional Neuromodulation Ltd
  • University of Southern California, Los Angeles, California, United States, 90033
50A Pilot, Phase 2a, Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Safety and Tolerability, Efficacy, and Pharmacokinetics of AD-35 in Subjects With Mild to Moderate Alzheimer's DiseaseZhejiang Hisun Pharmaceutical Co. Ltd.
  • Northern California Research, Sacramento, California, United States, 95821
  • Pacific Research Network, Inc., San Diego, California, United States, 92103
51A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's DiseaseAriBio Co., Ltd.
  • Advanced Clinical Research, Inc., Banning, California, United States, 92220
  • Northern California Research, Sacramento, California, United States, 95821
52Fall Detection and Prevention for Memory Care Through Real-time Artificial Intelligence Applied to Video: A Randomized Control TrialSafelyYou
  • SafelyYou, San Francisco, California, United States, 94107
53U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce RiskWake Forest University Health Sciences
  • Northern California, Sacramento, California, United States, 95616
54Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's DiseaseUniversity of California, San Diego
  • Clinical Teaching Facility (CTF-B102) at UCSD Medical Center, San Diego, California, United States, 92103
55Prazosin for Disruptive Agitation in Alzheimer's Disease (AD) (PEACE-AD)Alzheimer's Disease Cooperative Study (ADCS)
  • University of Southern California, Los Angeles, California, United States, 90033
  • University of California, San Diego (UCSD), San Diego, California, United States, 92093
56An Extension Study of ABBV-8E12 in Early Alzheimer's DiseaseAbbVie
57A Nonrandomized Evaluation of a Multidimensional Behavioral Intervention for Those at Risk for Alzheimer's DementiaUniversity of California, Davis
  • University of California Davis, Sacramento, California, United States, 95816
58Prevention of Alzheimer's Disease in Women: Risks and Benefits of Hormone Therapy -Continuation of: "The Kronos Early Estrogen Prevention Study (KEEPS)" Mayo Clinic IRB#2241-04-00Mayo Clinic
  • University of California San Francisco, San Francisco, California, United States, 94158
59A Randomized Pivotal Study of RenewTM NCP-5 for the Treatment of Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Dementia of the Alzheimer's TypeRenew Research, LLC
  • Irvine Clinical Research, Irvine, California, United States, 92614
60Allopregnanolone Regenerative Therapeutic for Early Alzheimer's Disease: IV to IM Bridging StudyUniversity of Arizona
  • University of Southern California - Alzheimer Disease Research Center - Healthcare Consultation Center II, Los Angeles, California, United States, 90033
61A Randomized , Double Blind, Placebo Controlled, 3-Arm Parallel Design Study to Evaluate the Effects of BPN14770 in Patients With Early Stage Alzheimer's DiseaseTetra Discovery Partners
  • CiTrials, Inc., Bellflower, California, United States, 90709
62GAIN Trial: A Randomized, Double-Blind, Placebo-Controlled Study of COR388 in Subjects With Alzheimer's DiseaseCortexyme Inc.
63Developing and Evaluating In-Home Supportive Technology for Dementia CaregiversUniversity of California, Berkeley
  • University of California, Berkeley, Berkeley, California, United States, 94720
  • Los Angeles County, Los Angeles, California, United States, 90011
64A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of MTAU9937A in Patients With Moderate Alzheimer's DiseaseGenentech, Inc.
  • Collaborative Neuroscience Network, Inc., Garden Grove, California, United States, 92845
  • Pharmacology Research Institute, Los Alamitos, California, United States, 90720
65MRI and PET Biomarkers for Cognitive Decline in Older AdultsUniversity of California, Irvine
  • University of California, Irvine, Irvine, California, United States, 92697
66A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's DiseaseEisai Inc.
67Development of Novel Measures of Cognition and Function for Alzheimer's Disease Prevention TrialsNew York State Psychiatric Institute
  • University of Southern California, Los Angeles, California, United States, 90033
68Tau Imaging With JNJ067University of California, Berkeley
  • University of California, Berkeley, Berkeley, California, United States, 94709
69Phase1a, Randomized Placebo-controlled, Single and Multiple Dose, Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral NNI-362 in Healthy Aged Volunteers 50 to 72 Years of AgeNeuronascent, Inc.
  • Parexel, International, Glendale, California, United States, 91206
70The PREVENTION Trial: Precision Recommendations for Environmental Variables, Exercise, Nutrition and Training Interventions to Optimize NeurocognitionJohn Wayne Cancer Institute
  • Pacific Brain Health Center, Santa Monica, California, United States, 90404
71An Open-label Study to Investigate the Effectiveness of a LifeSeasons NeuroQ Supplement in Addition to Four Bredesen Recommended Lifestyle Changes to Improve Cognitive Function in Healthy Adults Who Have One or More Risk Factors for Cognitive DeclineLifeSeasons Inc.
  • Kapoor Medical Center, Studio City, California, United States, 91604
72Interventional, Randomized, Double-blind, Placebo-controlled, Single-ascending-dose Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Lu AF87908 in Healthy Subjects and Patients With Alzheimer's DiseaseH. Lundbeck A/S
  • California Clinical Trials Medical Group, Los Angeles, California, United States, 91206-4007
73Lymphatic System Health in Alzheimer's DiseaseNeurological Associates of West Los Angeles
  • Westwood Open MRI, Los Angeles, California, United States, 90024
  • Neurological Associates of West Los Angeles, Santa Monica, California, United States, 90403
74Developing and Evaluating In-Home Supportive Technology for Caregivers of People With Dementia and Mild Cognitive ImpairmentUniversity of California, Berkeley
  • University of California, Berkeley, Berkeley, California, United States, 94720
75Compensation Training to Improve Everyday Functioning of Older Adults With Mild Cognitive Impairment and Subjective Cognitive Complaints: The Digital Memory NotebookUniversity of California, Davis
  • Alzheimer's Disease Center, University of California, Davis, Sacramento, California, United States, 95817
76Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (Aducanumab) in Subjects With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205Biogen
  • Neurology Center of North Orange County, Fullerton, California, United States, 92835
77The Use of Transcranial Focused Ultrasound for the Treatment of Neurodegenerative DementiasNeurological Associates of West Los Angeles
  • Neurological Associates of West LA, Santa Monica, California, United States, 90403
78Water-based Activity to Enhance Recall in Veterans: A Randomized Clinical TrialVA Office of Research and Development
  • VA Palo Alto Health Care System, Palo Alto, CA, Palo Alto, California, United States, 94304-1290
79An Open-Label, Multicenter, Rollover Study to Evaluate the Safety and Tolerability of Long-Term Administration of Gantenerumab in Participants With Alzheimer's DiseaseHoffmann-La Roche
  • Pacific Research Network - PRN, San Diego, California, United States, 92103
  • California Neuroscience Research Medical Group, Inc, Sherman Oaks, California, United States, 91403
80SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD): A Multi-center, Randomized, Double-Blind, Placebo-Controlled Safety and Biomarker Study of Pepinemab Anti-SEMA4D Antibody in Early-ADVaccinex Inc.
  • Pacific Research Network, Inc, San Diego, California, United States, 92103
81Evaluating the Effectiveness of an Online Small-Group Self-Management Workshop for Rural Caregivers of Individuals With Alzheimer's Disease and Related DementiasUniversity of California, San Francisco
  • University of California, San Francisco, San Francisco, California, United States, 94118
82Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's DiseaseEli Lilly and Company
83A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3372993 in Participants With Alzheimer's DiseaseEli Lilly and Company
  • Collaborative Neuroscience Network, Long Beach, California, United States, 90806
84A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's TypeAvanir Pharmaceuticals
  • Clinical Research Site, San Diego, California, United States, 92128
85Virtual Patient Behavioral Response Training for Family CaregiversPhotozig, Inc.
  • Photozig, Inc., Mountain View, California, United States, 94035-0128
86Feasibility of At-Home Telehealth Yoga for Treating Chronic PainPalo Alto Veterans Institute for Research
  • VA Palo Alto Health Care System, Palo Alto, California, United States, 94304
87Caring Light Project for Caregivers of Individuals With Alzheimer's DiseasePhotozig, Inc.
  • Photozig, Inc., Mountain View, California, United States, 94035-0128
88Open-Label Continuation Treatment Study With Levodopa - Carbidopa Intestinal Gel In Subjects With Advanced Parkinson's Disease And Severe Motor-Fluctuations Who Have Exhibited A Persistent And Positive Effect To Treatment In Previous StudiesAbbVie (prior sponsor, Abbott)
  • The Research Ctr Southern CA /ID# 49928, Carlsbad, California, United States, 92011-4219
89The Parkinson's Disease NeuroGenebank at Scripps Clinic RegistryScripps Translational Science Institute
  • Scripps Clinic, Torrey Pines, La Jolla, California, United States, 92037
  • Scripps Translational Science Institute, La Jolla, California, United States, 92037
90The Parkinson's Progression Markers Initiative (PPMI)Ken Marek, MD
91Molecular Analysis of Adult Human-derived Neural Stem CellsNeuroGeneration
  • Los Angeles Neurosurgical Institute, Los Angeles, California, United States, 90211
92Ongoing, Web-Based Genome-Wide Association Studies for Targeted Disease Initiatives23andMe, Inc.
  • Www.23Andme.Com/Pd, Mountain View, California, United States, 94043
93Parkinson's Foundation Quality Improvement InitiativeNational Parkinson Foundation
  • Parkinson's Institute and Clinical Center, Sunnyvale, California, United States, 94085
94Implantable Neurostimulator for the Treatment of Parkinson's DiseaseBoston Scientific Corporation
  • , Los Angeles, California, United States, 90048
  • Boston Scientific Clinical Research Information Toll Free Number, Valencia, California, United States, 91355
95A Multi-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-Directed Biomedical Research InitiativesSanguine Biosciences
  • Sanguine Biosciences, Los Angeles, California, United States, 91403
96Chronic Effects of Deep Brain Stimulation on Cortical Local Field Potentials in Parkinson's Disease and DystoniaUniversity of California, San Francisco
  • UCSF Surgical Movement Disorders Center, San Francisco, California, United States, 94115
97Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS RegistryBoston Scientific Corporation
  • Boston Scientific Clinical Research Toll-Free Number, Valencia, California, United States, 91355
98A Feasibility Clinical Trial of the Management of the Medically-Refractory Dyskinesia Symptoms of Advanced Idiopathic Parkinson's Disease With Unilateral Lesioning of the Globus Pallidum Using the ExAblate Transcranial SystemInSightec
  • Stanford University Medical Center, Stanford, California, United States, 94305
99Exercise Targeting Cognitive Impairment in Parkinson's DiseaseUniversity of Southern California
  • University of Southern California, Los Angeles, California, United States, 90033-4606
100A Phase 3, Open-Label Study of the Safety, Efficacy and Tolerability of Apomorphine Administered by Continuous Subcutaneous Infusion in Advanced Parkinson's Disease Patients With Unsatisfactory Control on Available TherapyUS WorldMeds LLC
  • , Loma Linda, California, United States, 92354
101Adaptive Closed Loop Neuromodulation and Neural Signatures of Parkinson's DiseaseStanford University
  • Stanford Movement Disorders Center, Stanford, California, United States, 94305-5235
102Brain Health RegistryUniversity of California, San Francisco
  • BrainHealthRegistry.org, San Francisco, California, United States, 94143
103An Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patients With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes)Sunovion
104An Open-label, Randomized 26-Week Study Comparing Levodopa-Carbidopa INteStInal Gel (LCIG) THerapy to Optimized Medical Treatment (OMT) on Non-Motor Symptoms (NMS) in Subjects With Advanced Parkinson's Disease - INSIGHTS StudyAbbVie
  • Parkinson's and Movement /ID# 161596, Fountain Valley, California, United States, 92708
105RESTORE: A Clinical Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa TherapyLundbeck Northera Ltd.
106A Multicenter, International, Open-label, Safety Study of ND0612, a Solution of Levodopa/Carbidopa Delivered Via a Pump System as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's DiseaseNeuroDerm Ltd.
107Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GZ/SAR402671 in Patients With Early-stage Parkinson's Disease Carrying a GBA Mutation or Other Pre-specified Variant.Genzyme, a Sanofi Company
108Antigen Presentation and Lymphocyte Response in Parkinson's DiseaseColumbia University
  • University of California San Diego School of Medicine, La Jolla, California, United States, 92037
109A Phase II, Randomized, Double-blinded, Placebo-controlled Trial of Liraglutide in Parkinson's DiseaseCedars-Sinai Medical Center
  • Cedars Sinai Medical Center, Los Angeles, California, United States, 90048
110The Stanford Parkinson's Disease Plasma (SPDP) Study: Intravenously-Administered Plasma From Young Donors for Treatment of Moderate Parkinson's DiseaseStanford University
  • Stanford Movement Disorders Clinic, Stanford, California, United States, 94304
111Post Market Clinical Follow Up Evaluating the Infinity Deep Brain Stimulation Implantable Pulse Generator SystemAbbott Medical Devices
  • Kaiser Permanente Sacramento Medical Center, Sacramento, California, United States, 94229
112Identification of Tear Biomarkers for Parkinson's Disease PatientsUniversity of Southern California
  • University of Southern California, Los Angeles, California, United States, 90033
113An Open-label Safety and Efficacy Study of VY-AADC01 Administered by MRI-Guided Convective Infusion Using a Posterior Trajectory Into the Putamen of Participants With Parkinson's Disease With Fluctuating Responses to LevodopaNeurocrine Biosciences
  • University of California, San Francisco (UCSF), San Francisco, California, United States, 94143
114More Than a Movement Disorder: Applying Palliative Care to Parkinson's DiseaseUniversity of Colorado, Denver
  • University of California, San Francisco, San Francisco, California, United States, 94143
115A Randomized, Double-Blind, Placebo-Controlled, 52-Week Phase II Study to Evaluate the Efficacy of Intravenous RO7046015/Prasinezumab (PRX002) in Participants With Early Parkinson's Disease With a 6-Year All-Participants-on-Treatment ExtensionHoffmann-La Roche
116Global Registry: ExAblate 4000 Transcranial MR Guided Focused Ultrasound (TcMRgFUS) of Neurological Disorders:InSightec
  • Stanford University, Stanford, California, United States, 94305
117Cortical Stimulation to Treat Mood and Behavioral Symptoms in Parkinson'sUniversity of California, San Francisco
  • UCSF Surgical Movement Disorders Center, San Francisco, California, United States, 94115
118Management of Parkinson's Disease Psychosis in Actual Practice (The INSYTE Study)ACADIA Pharmaceuticals Inc.
119A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, With an Active-Treatment Dose-Blinded Period, to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects With Parkinson's DiseaseBiogen
120A Pivotal Clinical Trial of the Management of the Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Idiopathic Parkinson's Disease With Unilateral Lesioning of the Globus Pallidum Using the ExAblate Neuro SystemInSightec
  • Stanford University Medical Center, Stanford, California, United States, 94305
121A Phase 3, Twelve-week Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily Compared to Its Individual Components in Subjects With Early Parkinson's Disease and to a Calibration Arm of Pramipexole ER.Pharma Two B Ltd.
122Cognitive Rehabilitation for Individuals With Parkinson's Disease and MCIVA Office of Research and Development
  • VA San Diego Healthcare System, San Diego, CA, San Diego, California, United States, 92161
123Safety and Efficacy of Droxidopa for Fatigue in Patients With ParkinsonismLoma Linda University
  • Loma Linda University Faculty Medical Offices - Neurology Clinic, Loma Linda, California, United States, 92354
124A Randomized, Sham Surgery Controlled, Double-blind, Multi-center, Phase 2 Clinical Trial, Evaluating the Efficacy and Safety of VY-AADC02 in Moderate to Advanced Parkinson's Disease Patients With Motor FluctuationsNeurocrine Biosciences
  • UC Irvine, Irvine, California, United States, 92697
  • UC Davis Health System, Sacramento, California, United States, 95817
125Microbiota Intervention to Change the Response of Parkinson's DiseaseUniversity of California, San Francisco
  • University of California San Francisco, San Francisco, California, United States, 94115
126Closed Loop Deep Brain Stimulation in Parkinson's Disease and Dystonia (Activa RC+S)University of California, San Francisco
  • University of California at San Francisco, San Francisco, California, United States, 94115
127Invasive Approach to Model Human Cortex-Basal Ganglia Action-Regulating NetworksUniversity of California, Los Angeles
  • Nader Pouratian, Los Angeles, California, United States, 90095
128Interventional, Randomized, Double-blind, Sequential-group, Placebo-controlled, Single-ascending-dose Study Investigating the Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Properties of Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's DiseaseH. Lundbeck A/S
  • California Clinical Trials Medical Group (CCTMG), Glendale, California, United States, 91206
129Effects of Osteopathic Manipulative Treatment (OMT) on Gait Biomechanics in Parkinson's Disease (OMT/PD)University of California, San Diego
  • University of California, San Diego, La Jolla, California, United States, 92093
130North American Prodromal Synucleinopathy ConsortiumWashington University School of Medicine
  • University of California Los Angeles, Los Angeles, California, United States, 90095
131A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of K0706 in Subjects With Early Parkinson's DiseaseSun Pharma Advanced Research Company Limited
  • Keck Hospital of USC, Los Angeles, California, United States, 90033
132Deep Brain Stimulation (DBS) Retrospective Outcomes StudyBoston Scientific Corporation
  • Boston Scientific Clinical Research Information Toll Free Number, Valencia, California, United States, 91355
133A Randomized Controlled Study to Compare the Safety and Efficacy of IPX203 With Immediate-Release Carbidopa-Levodopa in Parkinson's Disease Patients With Motor FluctuationsImpax Laboratories, LLC
134A Multicenter, Prospective, Longitudinal, Digital Assessment Study of Disease Progression in Subjects With Early, Untreated Parkinson DiseaseUniversity of Rochester
  • University of California San Francisco, San Francisco, California, United States, 94115
135An Observational, Long-Term Extension Study for Participants in Prior VY-AADC01 Clinical StudiesNeurocrine Biosciences
  • University of California, San Francisco, San Francisco, California, United States, 94143
136Evaluation of the Personal KinetiGraph™ (PKG™) to Improve Insight Into Parkinson's Disease Status (APPRISE)Global Kinetics Corporation
  • Sutter Health, Sacramento, California, United States, 95816
  • University of California, San Diego, California, United States, 92037
137A Phase 3, 4-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Autonomic FailureTheravance Biopharma
138The Effect of Adrenergic Blocker Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's DiseaseMichele Tagliati, MD
  • Cedars Sinai Medical Center, Los Angeles, California, United States, 90048
139A 52-Week, Open-label, Single-arm Study to Evaluate the Safety and Tolerability of 24-hour Daily Exposure of Continuous Subcutaneous Infusion of ABBV-951 in Subjects With Parkinson's DiseaseAbbVie
140A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate Safety, Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease-Related Constipation (KARMET)Enterin Inc.
141A Prospective, Randomized, Staggered-onset, Double Blinded, Sham-Controlled Study to Evaluate Peripheral Vibrotactile Coordinated Reset (CR) Stimulation for Parkinson's DiseaseCasey H. Halpern
  • Stanford University, Stanford, California, United States, 94305
142Rostock International Parkinson's Disease Study: an International, Multicenter, Epidemiological Observational StudyCentogene AG Rostock
  • Pharmacology Research Institute, Encino, California, United States, 91316
143An Open-label Extension Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease Patients With Motor FluctuationsImpax Laboratories, LLC
144A Double-Blind, Randomized, Three-Arm, Parallel-Group Study to Assess the Efficacy and Safety of Two Doses of Pridopidine Versus Placebo for the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's Disease (gLIDe)Prilenia
145TOPAZ: Trial of Parkinson's And Zoledronic Acid A Randomized Placebo-controlled Trial of Zoledronic Acid for the Prevention of Fractures in Patients With Parkinson's DiseaseCalifornia Pacific Medical Center Research Institute
  • Loma Linda University, Loma Linda, California, United States, 92350
146A Multicenter, Open Label Study to Evaluate Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Dementia.Enterin Inc.
  • Neuro Pain Medical Center, Fresno, California, United States, 93710
147Utilization of Target Ranges to Treat Patients With Parkinson's Disease by Objective Measurement Using the Personal KinetiGraph® (PKG®) Compared to Standard of Care Assessment (TARGET-PD)- A Randomized Controlled TrialGlobal Kinetics Corporation
148Mindfulness Based Stress Reduction for Parkinson's Disease: A Longitudinal StudyVA Office of Research and Development
  • VA San Diego Healthcare System, San Diego, CA, San Diego, California, United States, 92161
149A Multicenter, Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Clinical Trial, Investigating the Efficacy, Safety, and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless)NeuroDerm Ltd.
  • The Research Center of Southern California, Carlsbad, California, United States, 92011
150Bilateral Closed Loop Deep Brain Stimulation for Freezing of Gait Using Neural and Kinematic FeedbackStanford University
  • Stanford University, Stanford, California, United States, 94305
151Parkinson's Foundation: PD Generation: Mapping the Future of Parkinson's DiseaseParkinson's Foundation
  • University of California San Diego (UCSD), La Jolla, California, United States, 92093
152Decision Making Among Older Adults: the AUTO StudyUniversity of Colorado, Denver
  • University of California, San Diego, La Jolla, California, United States, 92037
153A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Parkinson's DiseaseProgenaBiome
  • ProgenaBiome, Ventura, California, United States, 93003
154A Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment Associated With Parkinson's DiseaseAptinyx
  • Aptinyx Clinical Site, Fresno, California, United States, 93710
155Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 36 Weeks of Treatment With NLY01 in Early-stage Parkinson's DiseaseNeuraly, Inc.
156A Pilot Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose QuetiapineACADIA Pharmaceuticals Inc.
157Open-Label Safety Study of Glial Cell Line-Derived Neurotrophic Factor Gene Transfer (AAV2- GDNF) in Parkinson's DiseaseBrain Neurotherapy Bio, Inc.
  • University of California Irvine, Irvine, California, United States, 92697
  • University of California San Francisco, San Francisco, California, United States, 94103
158A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of CVN424 in Parkinson's Disease Patients With Motor FluctuationsCerevance Beta, Inc.
  • Collaborative Neuroscience Network, LLC, Long Beach, California, United States, 90806
  • SC3 Research - Pasadena, Pasadena, California, United States, 91105
159A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses of Tavapadon in Early Parkinson's Disease (TEMPO-1 TRIAL)Cerevel Therapeutics, LLC
  • Fountain Valley, California, Fountain Valley, California, United States, 92708
160The Effect of Adrenergic Blocker Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease: A Follow up StudyCedars-Sinai Medical Center
  • Cedars Sinai Medical Center, Los Angeles, California, United States, 90048
161A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon in Early Parkinson's Disease (TEMPO-2 Trial)Cerevel Therapeutics, LLC
  • Fresno, California, Fresno, California, United States, 93710
162The Use of Transcranial Focused Ultrasound for the Treatment of Neurodegenerative DementiasNeurological Associates of West Los Angeles
  • Neurological Associates of West LA, Santa Monica, California, United States, 90403
163Study in Parkinson Disease of Exercise Phase 3 Clinical Trial: SPARX3Northwestern University
  • University of Southern California, Los Angeles, California, United States, 90007
164A Study to Analyze Features of Dysphonia and Tremor in PD Patients to Aid in the Development of an Accurate Diagnostic Tool for Early-Detection of PDGoalspal LLC
  • Goalspal LLC, Pleasanton, California, United States, 94566
165A 16-Week Open-Label Study of the Effects of Treatment With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease PsychosisACADIA Pharmaceuticals Inc.
  • Neurology Center of North Orange County, Fullerton, California, United States, 92835
166A 2-Part, Open Label, Adaptive, Single and/or Multiple Oral Dose, Safety, Tolerability, and Food Effect Trial of CVL-751 in Subjects With Parkinson's DiseaseCerevel Therapeutics, LLC
  • CNS Network, Long Beach, California, United States, 90806
167A Randomized, Double-blind, Placebo-Controlled, 2-Period Crossover, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral TAK-071 in Parkinson Disease Patients With Cognitive Impairment and an Elevated Risk of FallsTakeda
  • Collaborative Neuroscience Network, LLC, Torrance, California, United States, 90502
  • Cedars Sinai Medical Center, West Hollywood, California, United States, 90048-1804
168A Randomized, Double-Blind, Placebo-Controlled, Two-Part Study in Parkinson's Disease Patients With Dyskinesia to Assess the Efficacy and Safety/Tolerability of Fixed Dose Combinations of JM-010 and Its Individual ComponentsBukwang Pharmaceutical
  • Bukwang Investigator site, Fountain Valley, California, United States, 92704
  • Bukwang Investigator site, Fullerton, California, United States, 92835
169A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy, Safety and Tolerability of ABBV-951 to Oral Carbidopa/Levodopa in Advanced Parkinson's Disease PatientsAbbVie
170Evaluating the Effectiveness of an Online Small-Group Self-Management Workshop for Rural Caregivers of Individuals With Alzheimer's Disease and Related DementiasUniversity of California, San Francisco
  • University of California, San Francisco, San Francisco, California, United States, 94118
171Mindfulness-based Cognitive Therapy for People With Parkinson's Disease and CaregiversUniversity of California, San Francisco
  • University of California, San Francisco, San Francisco, California, United States, 94143
172An Open-Label Evaluation of the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive ImpairmentSage Therapeutics
  • Sage Investigational Site, Long Beach, California, United States, 90806
173The Parkinson's Progression Markers Initiative (PPMI) 2.0 Clinical -Establishing a Deeply Phenotyped PD CohortMichael J. Fox Foundation for Parkinson's Research
174A Multicenter, Non-Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Orally Administered ENT-01 in Improving Constipation and Neurologic Symptoms in Patients With Parkinson's Disease and Constipation Over a 14-week PeriodEnterin Inc.
  • The Parkinson's and Movement Disorder Institute, Fountain Valley, California, United States, 92708
  • SC3 Research - Pasadena, Pasadena, California, United States, 91105
175Subcortical-cortical Network Dynamics of Anesthesia and ConsciousnessUniversity of California, Los Angeles
  • Nader Pouratian, Los Angeles, California, United States, 90095
176A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon as Adjunctive Therapy for Parkinson's Disease in Levodopa-Treated Adults With Motor Fluctuations (TEMPO-3 Trial)Cerevel Therapeutics, LLC
  • Fountain Valley, California, Fountain Valley, California, United States, 92708
  • Frenso, California, Fresno, California, United States, 93710
177Long-term, Prospective,Multinational, Parallel-cohort Study Monitoring Safety in Patients With MS Newly Started With Fingolimod Once Daily or Treated With Another Approved Disease-modifying TherapyNovartis Pharmaceuticals
178A Double-Blind, Placebo Controlled Trial of Estriol Treatment in Women With Multiple Sclerosis: Effect on Cognition.University of California, Los Angeles
  • University of California Los Angeles, Los Angeles, California, United States, 90095
179A 2 Year, Double-blind, Randomized, Multicenter, Active-controlled Core Phase to Evaluate Safety & Efficacy of Daily Fingolimod vs Weekly Interferon β-1a im in Pediatric Patients With Multiple Sclerosis and 5 Year Fingolimod Extension PhaseNovartis Pharmaceuticals
180A Multi-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-Directed Biomedical Research InitiativesSanguine Biosciences
  • Sanguine Biosciences, Los Angeles, California, United States, 91403
181A Phase II Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple SclerosisImmune Response BioPharma, Inc.
  • CRO, San Diego, California, United States, 92129
182A Phase IIb Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis Slowing Disease Progression Via VaccinationImmune Response BioPharma, Inc.
  • CRO, San Diego, California, United States, 92129
183A Phase I Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple SclerosisImmune Response BioPharma, Inc.
  • CRO, San Diego, California, United States, 92129
184Brain Health RegistryUniversity of California, San Francisco
  • BrainHealthRegistry.org, San Francisco, California, United States, 94143
185A Randomized, Double-Blind, Parallel-Group, Placebo Controlled Trial to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Clemastine Fumarate as a Remyelinating Agent in Acute Optic NeuritisUniversity of California, San Francisco
  • University of California San Francisco, San Francisco, California, United States, 94158
186International Deprexis Trial in Multiple Sclerosis (IDEMS) - a Multicenter Randomized Controlled TrialCharite University, Berlin, Germany
  • Cedars-Sinai Medical Center, Los Angeles, California, United States, 90048
187Teriflunomide Pregnancy Outcome Exposure Registry: An OTIS Autoimmune Diseases in Pregnancy ProjectSanofi
  • Investigator, San Diego, California, United States, 92093
188A Pragmatic Trial to Evaluate the Intermediate-term Effects of Early, Aggressive Versus Escalation Therapy in People With Multiple SclerosisJohns Hopkins University
189An Open-Label, Single-Arm 4-Year Study to Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients With Progressive Multiple SclerosisHoffmann-La Roche
  • MS Center of California, Newport Beach, California, United States, 92663
  • SC3 Research Group, Inc, Pasadena, California, United States, 91105
190Fecal Microbiota Transplantation (FMT) of FMP30 in Relapsing-Remitting Multiple Sclerosis: A Phase 1b Clinical Trial to Evaluate Feasibility, Safety, Tolerability and Effects on Immune FunctionUniversity of California, San Francisco
  • UCSF Multiple Sclerosis Center, San Francisco, California, United States, 94158
191Exploring the Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Patients With Advancing Forms of Relapsing Multiple Sclerosis: A 6-month Open Label, Multi- Center Phase IIIb StudyNovartis Pharmaceuticals
192Assessing the Induction of Long-term Immune Regulation Following Treatment With Lemtrada® (Alemtuzumab).University of Southern California
  • University of Southern California, Department of Neurology, Los Angeles, California, United States, 90033
193An Open-label, Single Arm, Multi-center Extension Study Evaluating Long-term Safety, Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple SclerosisNovartis Pharmaceuticals
194A High-Performance ECoG-based Neural Interface for Communication and Neuroprosthetic ControlUniversity of California, San Francisco
  • University of California San Francisco, San Francisco, California, United States, 94158
195Computerized Cognitive Training for Patients With Cognitive Deficits Due to Multiple Sclerosis: a Pilot StudyRiley Bove, MD
  • Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California, United States, 94158
196A Phase 2 Open-label Multicenter Study to Evaluate the Safety and Efficacy of Repeated Administration of NurOwn® [Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors (NTF), MSC-NTF] Cells in Participants With Progressive MSBrainstorm-Cell Therapeutics
  • University of Southern California, Los Angeles, California, United States, 90033
  • Stanford University School of Medicine, Redwood City, California, United States, 943063
197A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)National Cancer Institute (NCI)
  • Stanford Cancer Institute Palo Alto, Palo Alto, California, United States, 94304
  • University of California Davis Comprehensive Cancer Center, Sacramento, California, United States, 95817
198Feasibility of the Multiple Sclerosis Performance Test for Assessment of Functional Performance Measures in Patients With Multiple SclerosisBiogen
  • Research Site, Berkeley, California, United States, 94705
  • Research Site, Los Angeles, California, United States, 90033-5310
199Cladribine Tablets: Observational Evaluation of Effectiveness and Patient-Reported Outcomes (PROs) in Suboptimally Controlled Patients Previously Taking Oral or Infusion Disease-Modifying Drugs (DMDs) for Relapsing Forms of Multiple Sclerosis (RMS) (MASTER-2)EMD Serono Research & Development Institute, Inc.
200Cladribine Tablets: Observational Evaluation of Effectiveness and Patient-Reported Outcomes (PROs) in Suboptimally Controlled Patients Previously Taking Injectable Disease-Modifying Drugs (DMDs) for Relapsing Forms of Multiple Sclerosis (RMS) (CLICK-MS)EMD Serono Research & Development Institute, Inc.
201An Open-Label, Randomized, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in Pediatric Subjects Aged 10 to Less Than 18 Years for the Treatment of Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label ExtensionBiogen
  • Research Site, La Jolla, California, United States, 92024
202A Phase II Randomized, Double-Blind, Parallel-Group, Placebo Controlled Delayed-Start Trial to Assess the Efficacy, Safety, and Tolerability of Bazedoxifene Acetate (BZA) as a Remyelinating Agent in Patients With Multiple SclerosisRiley Bove, MD
  • Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California, United States, 94158
203A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple SclerosisHoffmann-La Roche
  • Arcadia Neurology Center, Arcadia, California, United States, 91006
204A Randomized, Crossover Pilot Trial of Melatonin for Sleep Disturbance in Adults With Multiple Sclerosis (MS)University of California, San Francisco
  • University of California, San Francisco, San Francisco, California, United States, 94158
205A Multicenter Randomized Controlled Trial of Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Treatment-Resistant Relapsing Multiple Sclerosis (ITN077AI)National Institute of Allergy and Infectious Diseases (NIAID)
  • Stanford Multiple Sclerosis Center, Palo Alto, California, United States, 94304
206The Impact of a Planned 12-week Dosing Interruption of Natalizumab on Immune Cell Trafficking, Pharmacokinetic (PK)/Pharmacodynamic (PD) Parameters, and Multiple Sclerosis (MS) Disease Stability.Berkovich, Regina MD, PhD Inc.
  • Regina Berkovich MD, PhD Inc., West Hollywood, California, United States, 90048
207An Open-Label, Parallel-Group Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple SclerosisHoffmann-La Roche
  • Loma Linda University health, Loma Linda, California, United States, 92354
  • University of California San Francisco, San Francisco, California, United States, 94117
208A Phase III Study in Subjects With Relapsing Forms of Multiple Sclerosis (RMS) to Asses Efficacy, Safety and Tolerability of GA Depot, a Long Acting IM Injection of Glatiramer Acetate, Once Monthly Compared to PlaceboMapi Pharma Ltd.
209A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)Celgene
210Decision Making Among Older Adults: the AUTO StudyUniversity of Colorado, Denver
  • University of California, San Diego, La Jolla, California, United States, 92037
211A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Multiple SclerosisProgenaBiome
  • ProgenaBiome, Ventura, California, United States, 93003
212A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With Teriflunomide, in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and SafetyMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
  • Research Site 642, Long Beach, California, United States, 90806
  • Research Site 644, Pasadena, California, United States, 91105
213A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With Teriflunomide, in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and SafetyMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
214A Single-arm, Prospective, Multicentre, Open-label Study to Evaluate Ofatumumab Treatment Effectiveness and Patient Reported Outcomes in Patients With Relapsing Multiple Sclerosis Transitioning From Dimethyl Fumarate or Fingolimod TherapyNovartis Pharmaceuticals
  • Novartis Investigative Site, Fullerton, California, United States, 92835
215An Open-Label, Multicenter Study to Assess Disease Activity and Biomarkers of Neuronal Damage in Minority Patients With Relapsing Multiple Sclerosis Receiving Treatment With OcrelizumabGenentech, Inc.
  • USC Keck School Of Medicine, Los Angeles, California, United States, 90033
216Monoclonal Antibodies in Mothers\' Milk and Infants: Ocrelizumab in BreastmilkUniversity of California, San Francisco
  • University of California, San Francisco, San Francisco, California, United States, 94158
217Exploratory Study of Entire-body PET Scans for Multiple SclerosisBrain Health Alliance
  • Brain Health Alliance, Ladera Ranch, California, United States, 92694
218A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS)Sanofi
  • Investigational Site Number 8400045, Long Beach, California, United States, 90806
  • Investigational Site Number 8400088, Torrance, California, United States, 90502
219Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis OnsetUniversity of California, San Francisco
  • University of California San Francisco, San Francisco, California, United States, 94158
220Effects of Non-invasive Transcranial Electrical Stimulation on Cognition in Patients With Multiple SclerosisUniversity of California, San Francisco
  • UCSF Sandler Neurosciences Center, San Francisco, California, United States, 94158
221Central Vein Sign: a Diagnostic Biomarker in Multiple SclerosisThe Cleveland Clinic
  • Cedars-Sinai Medical Center, Los Angeles, California, United States, 90048
  • University of Southern California, Los Angeles, California, United States, 90089
222A Phase IIIb Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple SclerosisHoffmann-La Roche
223A Phase IIIB Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple SclerosisHoffmann-La Roche
224BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With TetraplegiaLeigh R. Hochberg, MD, PhD.
  • Stanford University School of Medicine, Stanford, California, United States, 94305
225Multi-centered Double Blind, Placebo Controlled Study Evaluating the Safety and Efficacy of Memantine at 20 mg BID in Patients With ALSUniversity of Kansas Medical Center
  • UC Irvine, Irvine, California, United States, 92868
226Phenotype, Genotype & Biomarkers in ALS and Related DisordersUniversity of Miami
  • Stanford University, Palo Alto, California, United States, 94304
  • University of California San Diego (UCSD), San Diego, California, United States, 92093
227Rare Diseases Clinical Research Network Advancing Research and Treatment for Frontotemporal Lobar Degeneration [ARTFL]: Research Projects 1 & 2University of California, San Francisco
  • University of California, Los Angeles, Los Angeles, California, United States, 90095
228A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB067 Administered to Adult Subjects With Amyotrophic Lateral Sclerosis and Confirmed Superoxide Dismutase 1 MutationBiogen
  • University of California San Diego Medical Center, La Jolla, California, United States, 92093-0949
229Genomic Translation for Amyotrophic Lateral Sclerosis CareColumbia University
  • Cedar Sinai Medical Center, Los Angeles, California, United States, 90048
230Fluid Biomarkers With Deep Phenotyping in Patients With ALSBarrow Neurological Institute
  • University of California, Irvine, Dept. of Neurology, Orange, California, United States, 92868
231An Extension Study to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB067 Administered to Previously Treated Adults With Amyotrophic Lateral Sclerosis Caused by Superoxide Dismutase 1 MutationBiogen
  • Research Site, La Jolla, California, United States, 92093-0949
232A Phase 3, Randomized Double-Blind, Placebo-Controlled Multicenter Study to Evaluate Efficacy and Safety of Repeated Administration of NurOwn® (Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors) in Participants With ALSBrainstorm-Cell Therapeutics
  • University of California Irvine Alpha Stem Cell Clinic, Irvine, California, United States, 92697
  • Cedars-Sinai Medical Center, Los Angeles, California, United States, 90048
233Clinical Procedures to Support Research in ALS (CAPTURE-ALS)University of Miami
  • Stanford University, Palo Alto, California, United States, 94304
  • California Pacific Medical Center, San Francisco, California, United States, 94115
234A Phase 3, Randomised, Placebo-Controlled Trial of Arimoclomol in Amyotropic Lateral SclerosisOrphazyme
235A Phase 1 Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 Administered Intrathecally to Adults With C9ORF72-Associated Amyotrophic Lateral SclerosisBiogen
  • Research Site, La Jolla, California, United States, 92037-0886
  • Research Site, Los Angeles, California, United States, 90048
236Open Label, Non-randomized Extension Trial to Assess Long Term Safety and Efficacy of Arimoclomol in Subjects With Amyotropic Lateral Sclerosis Who Have Completed the ORARIALS-01 TrialOrphazyme
237A Phase 1, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adult Participants With Amyotrophic Lateral SclerosisBiogen
  • University of California San Diego Medical Center, San Diego, California, United States, 92121
238A Pilot Study to Assess Transmembrane Electromyography (TM-EMG) for the Assessment of Neuromuscular Function in the OropharynxPowell Mansfield Inc.
  • SENTA Clinic, San Diego, California, United States, 92108
239A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 12 Month Clinical Trial to Evaluate the Efficacy and Safety of MN-166 (Ibudilast) Followed by Open-Label Extension Phase in Subjects With Amyotrophic Lateral SclerosisMediciNova
  • University of California, Orange, California, United States, 92868
240Oxidative Markers and Efficacy in Amyotrophic Lateral Sclerosis (ALS) Phenotypes Treated With EdaravoneLoma Linda University
  • Loma Linda University, Loma Linda, California, United States, 92354
241A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Amyotrophic Lateral SclerosisProgenaBiome
  • ProgenaBiome, Ventura, California, United States, 93003
242A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (ALS)Alexion Pharmaceuticals
243Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)Mitsubishi Tanabe Pharma America Inc.
244An Extension Study to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB078 Administered to Previously Treated Adults With C9ORF72-Associated Amyotrophic Lateral SclerosisBiogen
  • Research Site, La Jolla, California, United States, 92037-0886
  • Research Site, Palo Alto, California, United States, 94304
245HEALEY ALS Platform TrialMerit E. Cudkowicz, MD
  • Loma Linda University Health, Loma Linda, California, United States, 92354
246ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)Mayo Clinic
  • University of California, Los Angeles, Los Angeles, California, United States, 90095
247A Phase 2a Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Study of Intravenous ANX005 in Subjects With Amyotrophic Lateral Sclerosis (ALS)Annexon, Inc.
  • Annexon Investigational Site 01, Irvine, California, United States, 92868

Disclaimer

CNS is independent of and does not evaluate, endorse, or have responsibility for any of the studies listed.

Back To Top